Neutralizing antibodies for the prevention and treatment of COVID-19

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through the receptor-binding domain (RBD) in the S1 subunit of the viral spike (S) protein. This event is followed by virus–cell membrane fusion mediated by the S2 subunit, which allows virus entry into the host cell. Therefore, the SARS-CoV-2 S protein is a key therapeutic target, and prevention and treatment of coronavirus disease 2019 (COVID-19) have focused on the development of neutralizing monoclonal antibodies (nAbs) that target this protein. In this review, we summarize the nAbs targeting SARS-CoV-2 proteins that have been developed to date, with a focus on the N-terminal domain and RBD of the S protein. We also describe the roles that binding affinity, neutralizing activity, and protection provided by these nAbs play in the prevention and treatment of COVID-19 and discuss the potential to improve nAb efficiency against multiple SARS-CoV-2 variants. This review provides important information for the development of effective nAbs with broad-spectrum activity against current and future SARS-CoV-2 strains.

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

“…For patients with B-cell aplasia or about to receive post-Allo-HSCT rituximab therapy, other strategies such as neutralizing antibodies for the prevention of COVID-19 infection should be also explored. 13 …”

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies

“…This study is a randomized, placebo-controlled study where 6420 participants were recruited (Clinical trial no: NCT04425629; ClinicalTrials.gov ). In November 2020, US-FDA provided emergency approval for the use of the two neutralizing antibodies such as imdevimab (REGN10987) and casirivimab (REGN10933) ( Du et al, 2021 ; Hurt and Wheatley, 2021 ). Presently, imdevimab and casirivimab combination (REGN-COV2) is entitled as “antibody cocktail.” Another antibody named bamlanivimab (LY-CoV555) is also called LY3819253.…”

Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2

“…The RBD domain of the SARS-CoV-2 spike protein (Figure 1A) is a validated component of SARS-CoV-2 vaccines [5] and the main target for the development of effective COVID-19 antibodies. Being the critical sequence for interaction with human cells, it contains both epitopes for antibody neutralization [13] and T cell recognition [7].…”